DV
Dividend Vision

INMB — INmune Bio Inc

INmune Bio Inc (INMB)

Total return is -72.8% over the past 7.5 years, 291.9 points behind SPY at 219.1%. Its deepest 1-year drawdown was 56.2%.

INmune Bio Inc. is a clinical-stage immunology company developing drugs to reprogram the innate immune system for treating hematologic malignancies, solid tumors, and chronic inflammation, with programs including INKmune (Phase 1 for myelodysplastic syndrome), INB03 (Phase II for breast cancer), XPro1595 (Alzheimer's disease and treatment-resistant depression), and CORDstrom (cell suspension therapy). The company does not currently distribute dividends. INmune Bio appeals to investors focused on early-stage biotechnology with potential for significant capital appreciation, as it remains pre-revenue and has not yet achieved profitability.

INMB key facts

Asset type
Stock
Asset class
Equity
Inception date
02/04/2019
Last close
$2.17
Market cap
$52,372,960
Average volume
462033.0
Beta
0.977
Payout ratio
0.0
Forward P/E
0.0
EPS
$-1.61